Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

被引：41

作者：

Araki, Takuya ^{[1
,2
]}

Yashima, Hideaki ^{[1
,2
]}

Shimizu, Kimihiro ^{[3
]}

Aomori, Tohru ^{[1
,2
,4
]}

Hashita, Tadahiro ^{[2
]}

Kaira, Kyoichi ^{[5
]}

Nakamura, Tomonori ^{[1
,2
]}

Yamamoto, Koujirou ^{[1
,2
]}

机构：

[1] Gunma Univ, Grad Sch Med, Dept Clin Pharmacol, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan

[2] Gunma Univ Hosp, Dept Pharm, Maebashi, Gunma 3718511, Japan

[3] Gunma Univ, Grad Sch Med, Dept Thorac & Visceral Organ Surg, Maebashi, Gunma 3718511, Japan

[4] Gunma Univ, Grad Sch Med, Ctr Med Educ, Maebashi, Gunma 3718511, Japan

[5] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gunma 3718511, Japan

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2012年 / 6卷

关键词：

gefitinib; EGFR; KRAS; NSCLC; lung cancer;

D O I：

10.4137/CMO.S7340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.

引用

页数：15

共 93 条

[1]

Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma [J].

Araki, Takuya ;

Shimizu, Kimihiro ;

Nakamura, Tomonori ;

Baba, Masaru ;

Kawai, Yuki ;

Nakamura, Katsunori ;

Mitani, Yasumasa ;

Obayashi, Kyoko ;

Aomori, Tohru ;

Fujita, Yukiyoshi ;

Miyamae, Yohei ;

Kakegawa, Seiichi ;

Kaira, Kyoichi ;

Lezhava, Alexander ;

Hayashizaki, Yoshihide ;

Takeyoshi, Izumi ;

Yamamoto, Koujirou .

ONCOLOGY REPORTS, 2011, 26 (05) :1213-1219

[2]

Usefulness of Peptide Nucleic Acid (PNA)-Clamp Smart Amplification Process Version 2 (SmartAmp2) for Clinical Diagnosis of KRAS Codon 12 Mutations in Lung Adenocarcinoma Comparison of PNA-Clamp SmartAmp2 and PCR-Related Methods [J].

Araki, Takuya ;

Shimizu, Kimihiro ;

Nakamura, Katsunori ;

Nakamura, Tomonori ;

Mitani, Yasumasa ;

Obayashi, Kyoko ;

Fujita, Yukiyoshi ;

Kakegawa, Seiichi ;

Miyamae, Yohei ;

Kaira, Kyoichi ;

Ishidao, Takefumi ;

Lezhava, Alexander ;

Hayashizaki, Yoshihide ;

Takeyoshi, Izumi ;

Yamamoto, Koujirou .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (01) :118-124

[3]

ErbB-targeted therapeutic approaches in human cancer [J].

Arteaga, CL .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :122-130

[4]

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients [J].

Bae, Nack Cheon ;

Chae, Myung Hwa ;

Lee, Myung Hoon ;

Kim, Kyung Mee ;

Lee, Eung Bae ;

Kim, Chang Ho ;

Park, Tae-In ;

Han, Sung Beom ;

Jheon, Sanghoon ;

Jung, Tae Hoon ;

Park, Jae Yong .

CANCER GENETICS AND CYTOGENETICS, 2007, 173 (02) :107-113

[5]

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[6]

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[7]

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[8]

Pharmacokinetics of gefitinib in humans:: The influence of gastrointestinal factors [J].

Bergman, Ebba ;

Forsell, Patrik ;

Persson, Eva M. ;

Knutson, Lars ;

Dickinson, Paul ;

Smith, Robert ;

Swaisland, Helen ;

Farmer, Matthew R. ;

Cantarini, Mireille V. ;

Lennernaes, Hans .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 341 (1-2) :134-142

[9]

MECHANISM OF EPIDERMAL GROWTH-FACTOR RECEPTOR AUTOPHOSPHORYLATION AND HIGH-AFFINITY BINDING [J].

BONISCHNETZLER, M ;

PILCH, PF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :7832-7836

[10]

Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J].

Cappuzzo, F ;

Gregorc, V ;

Rossi, E ;

Cancellieri, A ;

Magrini, E ;

Paties, CT ;

Ceresoli, G ;

Lombardo, L ;

Bartolini, S ;

Calandri, C ;

De Rosa, M ;

Villa, E ;

Crinò, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2658-2663

← 1 2 3 4 5 6 7 8 9 10 →